{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:09:45Z","timestamp":1790514585781,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.euroneuro.2012.03.003","type":"journal-article","created":{"date-parts":[[2012,4,14]],"date-time":"2012-04-14T01:34:16Z","timestamp":1334367256000},"page":"818-824","source":"Crossref","is-referenced-by-count":81,"title":["Geographical and temporal variations in clozapine prescription for schizophrenia"],"prefix":"10.1016","volume":"22","author":[{"given":"Jimmi","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"R\u00f8ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Schjerning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger J.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2012.03.003_bib1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/jcp.0b013e3180d0a6d4","article-title":"Early use of clozapine for poorly responding first-episode psychosis","volume":"27","author":"Agid","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib4","first-page":"75","article-title":"Contrasting clozapine prescribing patterns in the east and west?","volume":"29","author":"Chong","year":"2000","journal-title":"Ann. Acad. Med. Singapore"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1176\/appi.ps.56.3.320","article-title":"Comparison of clozapine use in Maryland and in Victoria, Australia","volume":"56","author":"Conley","year":"2005","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.jcp.0000096246.29231.73","article-title":"The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study","volume":"23","author":"Conley","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib7","first-page":"8","article-title":"Clozapine reduces violence and persistent aggression in schizophrenia","volume":"59","author":"Glazer","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/026988110201600208","article-title":"The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study","volume":"16","author":"Hayhurst","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/schbul\/sbl068","article-title":"Clozapine underutilization and discontinuation in African Americans due to leucopenia","volume":"33","author":"Kelly","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib11","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/appi.ajp.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/10398562.2010.525647","article-title":"Drug usage to alleviate the adverse effects of clozapine","volume":"19","author":"McKean","year":"2011","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/10398560802189896","article-title":"Prescribing and monitoring clozapine in Christchurch","volume":"16","author":"McKean","year":"2008","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib16","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1097\/00004714-199804001-00003","article-title":"The evolution of treatment resistance: biologic implications","volume":"18","author":"Meltzer","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib17","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4088\/JCP.v68n1115","article-title":"The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update","volume":"68","author":"Moore","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1403494810395825","article-title":"The Danish Psychiatric Central Research Register","volume":"39","author":"Mors","year":"2011","journal-title":"Scand. J. Public Health"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0269881108100320","article-title":"Psychiatrists' attitude towards and knowledge of clozapine treatment","volume":"24","author":"Nielsen","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","article-title":"Optimizing clozapine treatment","volume":"123","author":"Nielsen","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.euroneuro.2009.03.002","article-title":"Increased use of antibiotics in patients treated with clozapine","volume":"19","author":"Nielsen","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/11587800-000000000-00000","article-title":"Assessing QT interval prolongation and its associated risks with antipsychotics","volume":"25","author":"Nielsen","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1600-0447.2010.01576.x","article-title":"10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia","volume":"122","author":"Nielsen","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib24","article-title":"Risk factors for Ileus in patients with schizophrenia","author":"Nielsen","year":"2010","journal-title":"Schizophr. Bull"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib25","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hup.1181","article-title":"Haematological toxicity of clozapine and some other drugs used in psychiatry","volume":"26","author":"Nooijen","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib27","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.5694\/j.1326-5377.2003.tb05310.x","article-title":"Managing patients with \u201ctreatment-resistant\u201d schizophrenia","volume":"178","author":"Pantelis","year":"2003","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib28","first-page":"44","article-title":"Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices","volume":"55","author":"Peacock","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/oxfordjournals.schbul.a006851","article-title":"Subtyping schizophrenia according to outcome or severity: a search for homogeneous subgroups","volume":"27","author":"Roy","year":"2001","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1176\/appi.ps.59.5.567","article-title":"Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006","volume":"59","author":"Sernyak","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/YCO.0b013e32830e6dc4","article-title":"Psychotropic prescription practices in east Asia: looking back and peering ahead","volume":"21","author":"Tan","year":"2008","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib32","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/JCP.0b013e3181e5c0f7","article-title":"Use of antacid medication in patients receiving clozapine: a comparison with other second-generation antipsychotics","volume":"30","author":"Taylor","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.2011.01792.x","article-title":"Augmentation of clozapine with a second antipsychotic\u2014a meta-analysis","volume":"125","author":"Taylor","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2012.03.003_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.v64n0107","article-title":"Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review","volume":"64","author":"Taylor","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.03.003_bib35","unstructured":"WHO, 2012. World Health Organization, Collaborating Centre Drug Statistics Methodology."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12000594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12000594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T22:14:19Z","timestamp":1593987259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X12000594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0924977X12000594"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.03.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}